RxDoctor Payments Data

Anand Pandey, MD

Cardiovascular Disease · Tuscaloosa, ALNPI 1740274133

Payments from drug & device makers

$528in general payments, 2019–2025

Across 54 payments — averaging $9.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$157
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$108
  • Novo Nordisk$99
  • AstraZeneca$74
  • Abbott$28
  • Bayer$19
  • plus $44 from 3 others

What the payments were for

  • Food & beverage$528100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$528 in reported general payments places this provider in the 20th percentile of 292 cardiovascular disease providers in Alabama.

See all cardiovascular disease providers in Alabama

Medicare billing

Part B allowed, 2024
$324,498
Medicare patients
1,996
Services billed
5,821

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban712$551,944
JardianceEmpagliflozin273$205,096
EntrestoSacubitril/Valsartan207$166,829
XareltoRivaroxaban154$138,998
BrilintaTicagrelor90$47,310
MultaqDronedarone Hcl29$35,350
Repatha SureclickEvolocumab43$33,320
FarxigaDapagliflozin Propanediol17$16,303
Praluent PenAlirocumab13$11,271
Metoprolol Succinate597$9,430
Flecainide Acetate119$6,982
JanuviaSitagliptin Phosphate12$6,767
Nadolol33$4,718
Ranolazine ErRanolazine40$3,867
ClopidogrelClopidogrel Bisulfate333$3,607

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$16$205,096273 claims
NovartisEntresto$157$166,829207 claims
Johnson & JohnsonXarelto$13$138,998154 claims
AstraZenecaBrilinta, Farxiga$74$63,614107 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 292 cardiovascular disease providers in Alabama.

Other cardiovascular disease in Tuscaloosa

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →